Background Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody,
can result in durable responses in patients with melanoma who have progressed after …

Background Anti-programmed cell death receptor-1 (PD-1) antibodies represent an effective
treatment option for metastatic melanoma as well as for other cancer entities. They act via …

Although mutations may represent attractive targets for immunotherapy, direct identification
of mutated peptide ligands isolated from human leucocyte antigens (HLA) on the surface of …

Background Anti-programmed cell death 1 (PD-1) antibodies represent an effective treatment
option for metastatic melanoma and other cancer entities. They act via blockade of the PD-…

Chronic lymphocytic leukemia (CLL) is associated with a variety of immunologic disturbances.
Hypogammaglobulinemia and autoimmune phenomena are both often present in this …

Cytotoxic T-lymphocyte (CTL) responses can be generated against peptides derived from the
immunoglobulin (Ig) V region in some but not all patients. The main reason for this appears …

Characterizing the human leukocyte antigen (HLA) bound ligandome by mass spectrometry
(MS) holds great promise for developing vaccines and drugs for immune-oncology. Still, the …

Background The anti-programmed cell death-1 (PD-1) inhibitors pembrolizumab and nivolumab
alone or in combination with ipilimumab have shown improved objective response rates …

Systemic pan-tumor analyses may reveal the significance of common features implicated in
cancer immunogenicity and patient survival. Here, we provide a comprehensive multi-omics …

Adoptive cell therapy (ACT) has seen a steep rise of new therapeutic approaches in its
immune-oncology pipeline over the last years. This is in great part due to the recent approvals of …